Silence Therapeutics (SLN) Accounts Payables (2018 - 2026)

Silence Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 44.89% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (down 44.89% YoY), while the FY2025 annual figure was $13.4 million, down 18.56% from the prior year.
• Accounts Payables came in at $10.4 million for Q1 2026 at Silence Therapeutics, down from $13.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $18.8 million in Q1 2025 to a low of -$18.9 million in Q2 2024.
• A 5-year average of -$2.9 million and a median of -$13.3 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 204.11% in 2023 and jumped 241.41% in 2025, its largest moves.
• Silence Therapeutics' Accounts Payables stood at $14.8 million in 2022, then tumbled by 204.11% to -$15.4 million in 2023, then soared by 206.31% to $16.4 million in 2024, then dropped by 18.56% to $13.4 million in 2025, then decreased by 22.38% to $10.4 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $10.4 million, $13.4 million, and $17.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison